LAGUNA HILLS, Calif., Jan. 18, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Chief Executive Officer Kenneth L. Waggoner will conduct a shareholder conference call at 4:30 p.m. EST on Tuesday, February 7, 2017.
Commenting on the upcoming shareholder conference call, Mr. Waggoner said, “After what can only be described as a landmark moment in PharmaCyte’s history, we are excited to report on what was a positive pre-IND meeting with the U.S. FDA. We made excellent progress and received good advice and guidance toward the goal of filing our IND. We now have a clear path forward, and we will use this upcoming shareholder call to lay out that path for analysts, shareholders and the public.”
Management will provide the latest information to analysts and shareholders about PharmaCyte's upcoming clinical trial in locally advanced, inoperable pancreatic cancer (LAPC), the company’s interaction with the U.S. Food and Drug Administration (FDA) and respond to written questions. Analysts and shareholders are requested to submit questions they may have about PharmaCyte’s clinical development program via email to investorrelations@pharmacyte.com. Mr. Waggoner will respond to as many of the questions as possible in the time permitted for the call.
| Date: | February 7, 2017 |
| Time: | 4:30 p.m. EST |
| Telephone Number: | (515) 739-1030 |
| Access Code: | 915-603-449 |
Once the call has been completed, an audio replay will be available to the public. PharmaCyte will provide a telephone number and access code to listen to the recorded call.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®”. This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.
In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical studies and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations: PharmaCyte Biotech, Inc. Investor Relations Department Telephone: 917.595.2856 Email: Info@PharmaCyte.com